Original Manufacturer High Purity Tesamorelin

Excessive accumulation of visceral fat acts like an active "inflammatory factory," continuously releasing inflammatory factors, exacerbating insulin resistance, and creating a vicious cycle of "fat accumulation - metabolic disorder." Tesamorelin, by increasing growth hormone levels, not only reduces visceral fat but also improves insulin sensitivity, lowers triglycerides and LDL cholesterol, breaking this cycle at its root and providing metabolic syndrome patients with the dual benefits of "fat reduction + metabolic regulation."

Abnormal fat distribution not only affects health but also brings enormous psychological stress, leading to social avoidance, anxiety, and even depression. Tesamorelin helps patients regain confidence by improving abdominal bulges. This dual improvement, combining physiological and psychological benefits, makes it a "psychological support" agent for patients rebuilding their quality of life while treating lipodystrophy.

"Red Line Warnings" for Contraindications: Tesamorelin's effects depend on normal pituitary function; therefore, it is contraindicated in patients with pituitary lesions, a history of brain radiotherapy, or traumatic brain injury. Its mechanism of promoting growth hormone release may stimulate tumor growth; therefore, it is contraindicated in patients with active malignant tumors. Individuals with allergies to any component, pregnant women, and those planning pregnancy are also contraindicated. These "red lines" are fundamental prerequisites for ensuring medication safety.

Growth hormone can slightly increase insulin resistance; therefore, patients with diabetes or metabolic syndrome need to closely monitor their blood glucose levels during treatment to avoid fluctuations. Some patients may experience a visual contrast of "a thinner abdomen but a fatter face and limbs" in the early stages of treatment. This is a normal phenomenon due to the reduction of visceral fat and should be explained to patients beforehand to avoid misunderstandings leading to treatment interruption.

As a subcutaneous injection, it must be strictly administered at a fixed time each day to ensure stable growth hormone secretion rhythms. Injection sites should be rotated to avoid local induration or redness; the medication must be stored as required, and after reconstitution, it must be used within the prescribed time. These details directly affect the efficacy and safety of the drug.

The effects of Tesamorelin typically appear after 26 weeks of treatment. Continued use is necessary to maintain the effect, and visceral fat may gradually return after discontinuation. It is not a "one-and-done" weight-loss drug, but rather a "metabolic regulation tool" that needs to be used in conjunction with a healthy lifestyle (such as moderate exercise and a balanced diet). Only by adhering to standardized treatment can long-term metabolic improvement be achieved.